Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASH 2021
Pharma
Novartis has an idea why Kymriah failed in 2L lymphoma
Kymriah’s complete lack of showing came in stark contrast to the over 60% of reductions on event-free survival that Yescarta and Breyanzi reported.
Angus Liu
Dec 14, 2021 9:00am
Roche details Polivy's practice-changing data in 1L DLBCL
Dec 14, 2021 9:00am
Sanofi's Sarclisa, J&J's Darzalex clash in 4-drug myeloma trials
Dec 11, 2021 9:30am
BMS, Gilead lock horns in CAR-T for 2L lymphoma
Dec 11, 2021 8:30am
A trial win could bless Servier's Tibsovo with a 3rd cancer nod
Dec 11, 2021 7:01am
BeiGene fleshes out competitive Brukinsa data in first-line CLL
Nov 4, 2021 9:00am
